Lexicon jumps on diabetes data

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) jumped $0.69 (46%) to $2.20 on Thursday after reporting data from a Phase I trial of solid oral LX4211 to treat Type II diabetes. The sodium-glucose cotransporter type 2 ( SGLT2) inhibitor significantly increased total glucagon-like peptide-1 (GLP-1), active GLP-1 and peptide YY (PYY) from baseline (p=0.001, p=0.032 and p=0.004, respectively). The trial enrolled 12 patients and data will be presented at the JPMorgan Healthcare Conference in San Francisco on Monday. Lexicon said it plans to begin a Phase II drug-drug interaction study of the tablet this quarter, with a Phase IIb efficacy study to follow next quarter. ...